Genetic susceptibility to vaginal candidiasis

Medical Mycology

Volumn 41, Issue 2, 2003, Pages 143-147

  Calderon, L ^b   Williams, R ^b   Martinez, M ^b   Clemons, K V ^b   Stevens, D A ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Endocrinology; Immunogenetics; Vaginal candidiasis

Indexed keywords

ESTRADIOL; ESTROGEN;

ARTICLE; CANDIDA ALBICANS; CORRELATION ANALYSIS; ENDOCRINE DISEASE; ENDOCRINOLOGY; GAMETOGENESIS; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HISTOCOMPATIBILITY GENE; IMMUNOGENETICS; MOUSE; MOUSE STRAIN; MYCOSIS; NONHUMAN; RAT STRAIN; VAGINA CANDIDIASIS; ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INBRED STRAIN; OUTBRED STRAIN; PATHOGENICITY; PATHOPHYSIOLOGY;

CANDIDA ALBICANS;

ANIMALS; ANIMALS, INBRED STRAINS; ANIMALS, OUTBRED STRAINS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, INBRED BALB C;

EID: 0142200982     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.41.2.143.147     Document Type: Article

References (24)

1. Hilton E, Chandrasekaran V, Rindos P, et al. Association of recurrent candidal vaginitis with inheritance of Lewis blood group antigens. J Infect Dis 1995; 172: 1616-1619.
2. Hanson LH, Perlman AM, Clemons KV, et al. Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother 1991; 35: 1334-1337.
3. Clemons KV, Stevens DA. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-γ. Med Mycol 2000; 38: 213-219.
4. Sorensen KN, Wanstrom AA, Allen SD, et al. Efficacy of syringomycin E in a murine model of vaginal candidiasis. J Antibiotics 1998; 51: 743-749.
5. Ryley JF, McGregor S. Quantification of vaginal Candida albicans infections in rodents. J Med Vet Mycol 1986; 2: 455-460.
6. Sokal RR, Rohlf FJ. Biometry, 2nd edn. San Francisco: W.H. Freeman, 1981.
7. Stevens DA, Calderon L, Martinez M, et al. Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. J Antimicrob Chemother 2002; 50: 361-364.
8. Rhodes JC, Wicker LS, Urba WJ. Genetic control of susceptibility to Cryptococcus in mice. Infect Immun 1990; 29: 494-499.
9. Hector RF, Yee E, Collins MS. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990; 58: 1476-1478.
10. Byron JK, Clemons KV, McCusker JH, et al. Pathogenicity of Saccharomyces cerevisiae in complement factor five (C5) deficient mice. Infect Immun 1995; 63: 478-485.
11. Diez-Orejas R, Molero G, Navarro-Garcia F, et al. Reduced virulence of Candida albicans MKC1 mutants: a role for mitogen activated protein kinase in pathogenesis. Infect Immun 1997; 65: 833-837.
12. Morozumi PA, Halpern JW, Stevens DA. Susceptibility differences of inbred strains of mice to blastomycosis. Infect Immun 1981; 32: 160-168.
13. Morozumi PA, Brummer E, Stevens DA. Strain differences in resistance to infection reversed by route of challenge: studies in blastomycosis. Infect Immun 1981; 34: 623-625.
14. Bistoni F, Marconi P, Frati L, et al. Increase of mouse resistance to Candida albicans infection by thymosin alpha-1. Infect Immun 1982; 36: 609-614.
15. Hector RF, Domer JE, Carrow EW. Immune responses to Candida albicans in genetically distinct mice. Infect Immun 1982; 38: 1020-1028.
16. Ashman RB, Fulurija A, Papadimitriou JM. Strain-dependent differences in host response to Candida albicans infection in mice are related to organ susceptibility and infectious load. Infect Immun 1996; 64: 1866-1869.
17. Londono P, Gao XM, Bowe F, et al. Evaluation of the intranasal challenge route in mice as a mucosal model for Candida albicans infection. Microbiology 1988; 144: 2291-2298.
18. Fidel PL, Cutright JL, Sobel JD. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect Immun 1995; 63: 4191-4194.
19. Black CA, Eyers FM, Dunkley ML, et al. Major histocompatibility haplotype does not impact the course of experimentally induced murine vaginal candidiasis. Lab Animal Sci 1999; 49: 668-672.
20. Mulero-Marchese RD, Blank KJ, Sieck TG. Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization. J Infect Dis 1998; 178: 227-234.
21. Mulero-Marchese RD, Blank KJ, Sieck TG. Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization. Immunogenetics 1999; 49: 973-980.
22. Brummer E, Stevens DA. Anticryptococcal activity of macrophages: role of C5 sufficient serum, phagocytosis, mouse strain, L-arginine, and effect of fluconazole. Cell Immunol 1994; 157: 1-10.
23. Brummer E., Gilmore GL, Shadduck RK, et al. Development of macrophage anticryptococcal activity in vitro is dependent on endogenous M-CSF. Cell Immunol 1998; 189: 144-148.
24. Spearow JL, Doemeny P, Sera R, et al. Genetic variation in susceptibility to endocrine disruption by estrogen in mice. Science 1999; 285: 1259-1261.